WEBINAR: Tune in to Genomic and Genetic Testing for Active Surveillance Decision Making
Genomic and genetic testing has become increasingly important in recent years in diagnosing and treating prostate cancer. What's the difference between genetics and genomics? Can genomic testing offer guidance on whether prostate cancer poses a high risk in the long run? How does genomic testing guide care with active surveillance? Can this information help your children?
These are some of the questions that will be answered by Dr. Brian Helfand, urologist, and molecular biologist. Interested? Registration information below:
When: Tuesday, September 29, 2020, 6-7:30 p.m. CT
Submit questions: JoeG@ancan.org